Dataset Information

MmPlasIPAS17_LateStgOvCa

ABSTRACT: MmPlasma IPAS17 late stage ovarian cancer vs normal

INSTRUMENT(S): LTQ FT

ORGANISM(S): Mus Musculus

SUBMITTER: Sam Hanash

PROVIDER: PAe000322 | PeptideAtlas | 2008-12-31

REPOSITORIES: PeptideAtlas

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	PAe000322_4852_search.params.tar.gz	Other
	PAe000322_4852_searchdatabase_tandem.fasta	Fasta
	PAe000322_4852_tandem.params	Other
	PAe000322_README	Other
	PAe000322_Search_Results_4852_201106271412.properties	Other

Items per page:

1 - 5 of 10

Publications

A mouse plasma peptide atlas as a resource for disease proteomics.

Zhang Qing Q Menon Rajasree R Deutsch Eric W EW Pitteri Sharon J SJ Faca Vitor M VM Wang Hong H Newcomb Lisa F LF Depinho Ronald A RA Bardeesy Nabeel N Dinulescu Daniela D Hung Kenneth E KE Kucherlapati Raju R Jacks Tyler T Politi Katerina K Aebersold Ruedi R Omenn Gilbert S GS States David J DJ Hanash Samir M SM

Genome biology 20080603 6

We present an in-depth analysis of mouse plasma leading to the development of a publicly available repository composed of 568 liquid chromatography-tandem mass spectrometry runs. A total of 13,779 distinct peptides have been identified with high confidence. The corresponding approximately 3,000 proteins are estimated to span a 7 logarithmic range of abundance in plasma. A major finding from this study is the identification of novel isoforms and transcript variants not previously predicted from g ...[more]

PMID: 18522751

Similar Datasets

Project description:Introduction: Serous ovarian cancer is the leading cause of gynecological cancers, with a 5-year survival rate below 45% due in part to the nonspecific symptoms and lack of accurate screening for early detection. In comparison, patients diagnosed at an early stage have a five-year survival rate of 92%, demonstrating the urgent need for biomarkers for the early detection of disease. Serum from patients with serous ovarian cancer contain antibodies to tumor antigens that are potential biomarkers for early detection. The purpose of this study is to identify a panel of novel serum autoantibody (AAb) biomarkers for the early diagnosis of serous ovarian cancer. Methods: To detect AAb we probed high-density programmable protein microarrays (NAPPA) containing 10,247 antigens with sera from patients with serous ovarian cancer (n = 30 cases/ 30 healthy controls) and measured bound IgG. We identified 735 promising tumor antigens using cutoff values of 10% sensitivity at 95% specificity and K-value>0.8, as well as visual analysis and evaluated these with an independent set of serous ovarian cancer sera (n = 30 cases/ 30 benign disease controls/ 30 heathy controls). Thirty-nine potential tumor autoantigens were identified with sensitivities ranging from 3 to 39.7% sensitivity at 95% specificity and were retested using an orthogonal programmable ELISA assay. A total of 13 potential tumor antigens were identified for further validation using an independent ovarian cancer sera set (n = 44 cases/ 34 healthy controls). Sensitivities at 95% specificity were calculated and a serous ovarian cancer classifier was constructed. In addition, we evaluated a longitudinal study using blinded serous pre-diagnostic ovarian cancer sera (n = 9 cases/ 90 controls) to examine the value of three (CTAG1, CTAG2, and p53) of these AAb in comparison to CA 125. Results: We identified 11-AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) that distinguished serous ovarian cancer cases from healthy controls with a combined 45% sensitivity at 100% specificity. In our longitudinal analysis, p53- and CTAG-AAb were detected up to 9 months prior to ovarian cancer diagnosis and increased with CA 125 levels. Conclusion: These are potential circulating biomarkers for the early detection of serous ovarian cancer, and warrant confirmation in larger clinical cohorts. In addition, p53- and CTAG1/2-AAb are detected in a subset of women with ovarian cancer up to 9 months prior to clinical diagnosis. Their utility as a biomarker for early detection, beyond CA 125, warrant further investigation.